Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis
The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.
Psoriatic Arthritis
Synovitis Detected by Ultrasound in Psoriatic Arthritis in Remission
Underlying synovitis and enthesitis may go undetected in clinical findings, but can be detected by power Doppler ultrasounds.
Psoriatic Arthritis Improved With Etanercept Therapy
Etanercept therapy reduces clinical markers of disease activity in patients with psoriatic arthritis while stabilizing cardiovascular disease risk factors over a period of 5 years.
A New Biomarker for Disease Activity in Psoriatic Arthritis?
Serum amyloid A levels were found to significantly correlate with C-reactive protein levels in psoriatic arthritis.
Treatment-Resistant Psoriatic Arthritis Improved by Ixekizumab
Ixekizumab benefits patients with treatment-resistant psoriatic arthritis when administered over a 2- or 4-week period.
Updated Psoriatic Arthritis Outcome Measures Offer Greater Inclusion of Patient Concerns
Outcome measurement tools for psoriatic arthritis have been updated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis.
Remicade Biosimilar FDA-Approved
The FDA has approved Renflexis, the second approved biosimilar to Remicade.
Psoriatic Arthritis Risk Increased by Depression Among Patients With Psoriasis
Researchers have demonstrated that depression is a significant risk factor for progression from psoriasis to psoriatic arthritis.
Developing Biomarkers for Inflammatory Arthritis
Urinary proteomics may help identify biomarkers that can distinguish between different types of inflammatory arthritis.
Fatigue May Predict Depression, Joint Involvement in Psoriatic Disease
There were higher levels of fatigue in psoriatic arthritis vs psoriasis, and fatigue scores were linked to depression.
